review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Clive Page | Q29643391 |
William MacNee | Q38326286 | ||
Marc Miravitlles | Q40059112 | ||
American Thoracic Society | Q467061 | ||
P2093 | author name string | P J Barnes | |
M Cazzola | |||
V Brusasco | |||
P W Jones | |||
E F Wouters | |||
M P Rutten-van Mölken | |||
S D Sullivan | |||
D A Mahler | |||
K F Rabe | |||
P S Burge | |||
P Palange | |||
S I Rennard | |||
J A Wedzicha | |||
P M A Calverley | |||
F J Martinez | |||
R Stockley | |||
B Make | |||
M Pistolesi | |||
B R Celli | |||
D Parr | |||
European Respiratory Society Task Force on outcomes of COPD | |||
L G Franciosi | |||
P433 | issue | 2 | |
P921 | main subject | pharmacology | Q128406 |
biomarker | Q864574 | ||
P304 | page(s) | 416-469 | |
P577 | publication date | 2008-02-01 | |
P1433 | published in | European Respiratory Journal | Q12257435 |
P1476 | title | Outcomes for COPD pharmacological trials: from lung function to biomarkers | |
P478 | volume | 31 |
Q89939209 | A Nomogram for Predicting Severe Exacerbations in Stable COPD Patients |
Q35230811 | A bibliometric analysis of the 100 most influential papers on COPD |
Q44494841 | A model-based longitudinal meta-analysis of FEV1 in randomized COPD trials |
Q30578043 | A pilot survey on the quality of life in respiratory rehabilitation carried out in COPD patients with severe respiratory failure: preliminary data of a novel Inpatient Respiratory Rehabilitation Questionnaire (IRRQ) |
Q36278452 | A pragmatic cluster randomized controlled trial of early intervention for chronic obstructive pulmonary disease by practice nurse-general practitioner teams: Study Protocol |
Q62825758 | A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD |
Q36907994 | A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD |
Q26992071 | A review of the most common patient-reported outcomes in COPD--revisiting current knowledge and estimating future challenges |
Q38308369 | A review on airway biomarkers: exposure, effect and susceptibility. |
Q43418314 | ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients |
Q64087842 | Acceptance, adherence and dropout rates of individuals with COPD approached in telehealth interventions: a protocol for systematic review and meta-analysis |
Q38066977 | Aclidinium bromide for the treatment of chronic obstructive pulmonary disease |
Q43695468 | Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease |
Q38112092 | Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease |
Q35191130 | Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial |
Q87418827 | Aclidinium: in chronic obstructive pulmonary disease |
Q34521884 | Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial |
Q37822219 | Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine |
Q48009363 | Adequate continuous positive airway pressure therapy reduces mortality in Chinese patients with obstructive sleep apnea |
Q35046919 | Admission prevention in COPD: non-pharmacological management |
Q38797163 | Advances in Identifying Urine/Serum Biomarkers in Alpha-1 Antitrypsin Deficiency for More Personalized Future Treatment Strategies |
Q26772710 | Aeroparticles, Composition, and Lung Diseases |
Q23912608 | Agricultural work exposures and pulmonary function among hired farm workers in California (the MICASA study) |
Q38937853 | An ECLIPSE View of Alpha-1 Antitrypsin Deficiency |
Q37808058 | An update on the use of indacaterol in patients with COPD. |
Q33755801 | Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life |
Q37734436 | Arformoterol tartrate in the treatment of COPD. |
Q38038596 | Assessment of COPD wellness tools for use in primary care: an IPCRG initiative |
Q37287138 | Assessment of patients with chronic obstructive pulmonary disease |
Q47334748 | Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography. |
Q34432556 | Association between lung function and exacerbation frequency in patients with COPD. |
Q36412702 | Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients |
Q36408615 | Asthma symptom utility index: reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients |
Q24197535 | Beclometasone for chronic obstructive pulmonary disease |
Q38055149 | Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement |
Q37973657 | Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes |
Q47677150 | Bioequivalence of a Liquid Formulation of Alpha1-Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha1-PI) in Alpha1-Antitrypsin Deficiency |
Q40398456 | Biologic lung volume reduction in advanced upper lobe emphysema: phase 2 results |
Q45720028 | Biomarkers in COPD: is mortality the Holy Grail? |
Q37937720 | Biomarkers of therapeutic response in patients with chronic obstructive pulmonary disease: a critical review of the literature |
Q37012728 | Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease |
Q38109057 | Blood specimen biomarkers of inflammation, matrix degradation, angiogenesis, and cardiac involvement: a future useful tool in assessing clinical outcomes of COPD patients in clinical practice? |
Q36027413 | Bronchoabsorption; a novel bronchoscopic technique to improve biomarker sampling of the airway. |
Q34049219 | Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data |
Q38939466 | Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. |
Q38946604 | Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease |
Q42943788 | Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD |
Q84112341 | C reactive protein and alpha1-antitrypsin: relationship between levels and gene variants |
Q35637295 | COPD association and repeatability of blood biomarkers in the ECLIPSE cohort |
Q38154256 | COPD management: role of symptom assessment in routine clinical practice. |
Q36964961 | COPD: what is the unmet need? |
Q26766294 | Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs |
Q30388877 | Changes in cystic fibrosis airway microbial community associated with a severe decline in lung function |
Q34554816 | Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease |
Q37323319 | Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. |
Q41815663 | Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches |
Q38838404 | Chinese Herbal Medicine and Salmeterol and Fluticasone Propionate for Chronic Obstructive Pulmonary Disease: Systematic Review and Network Meta-Analysis |
Q34073318 | Chinese herbal medicine (weijing decoction) combined with pharmacotherapy for the treatment of acute exacerbations of chronic obstructive pulmonary disease |
Q38065457 | Chronic bronchial infection in COPD. Is there an infective phenotype? |
Q26801134 | Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life |
Q34658113 | Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease |
Q34500895 | Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. |
Q24235761 | Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease |
Q26471530 | Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease |
Q24200446 | Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease |
Q57817177 | Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis |
Q39399389 | Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis |
Q37490124 | Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease |
Q97530192 | Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial |
Q36385615 | Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression |
Q37930206 | Controversies in treatment of chronic obstructive pulmonary disease |
Q36384150 | Correlations between disease-specific and generic health status questionnaires in patients with advanced COPD: a one-year observational study |
Q37992679 | Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues |
Q36258855 | Cost-effectiveness of integrated COPD care: the RECODE cluster randomised trial |
Q33991002 | Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores |
Q38261881 | Dang shen [Codonopsis pilosula (Franch.) Nannf] herbal formulae for chronic obstructive pulmonary disease: a systematic review and meta-analysis. |
Q38068885 | Deciding what type of evidence and outcomes to include in guidelines: article 5 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report |
Q92665731 | Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression |
Q37610458 | Defining disease modification in chronic obstructive pulmonary disease |
Q38503383 | Defining exacerbations in chronic obstructive pulmonary disease |
Q38208244 | Defining phenotypes in COPD: an aid to personalized healthcare. |
Q43897461 | Demographic and clinical characteristics associated with quality of life in patients with chronic obstructive pulmonary disease |
Q35216364 | Depression and heart failure associated with clinical COPD questionnaire outcome in primary care COPD patients: a cross-sectional study. |
Q91788881 | Development and Validation of the Modified Patient-Reported Outcome Scale for Chronic Obstructive Pulmonary Disease (mCOPD-PRO) |
Q57035370 | Development of a core outcome set for trials investigating the long-term management of bronchiectasis |
Q37099911 | Development of the chronic obstructive pulmonary disease morning symptom diary (COPD-MSD) |
Q26751313 | Diagnosing COPD: advances in training and practice - a systematic review |
Q35956386 | Diffusion-weighted hyperpolarized 129Xe MRI in healthy volunteers and subjects with chronic obstructive pulmonary disease |
Q52679681 | Disease Management Plus Recommended Care versus Recommended Care Alone for Ambulatory COPD Patients. |
Q53062786 | Disease severity and symptoms among patients receiving monotherapy for COPD. |
Q54985483 | Distinct pain profiles in patients with chronic obstructive pulmonary disease. |
Q64229239 | Distinct skeletal muscle molecular responses to pulmonary rehabilitation in chronic obstructive pulmonary disease: a cluster analysis |
Q38091512 | Do we know the minimal clinically important difference (MCID) for COPD exacerbations? |
Q94512346 | Does the 6-minute walk test in hospitalized COPD patients exclusively correlate with lung function parameters or should psychological factors also be taken into account? |
Q35170142 | Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD. |
Q55430075 | Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT). |
Q37228266 | Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD. |
Q51677873 | Drug development for chronic lung disease--mission impossible? |
Q30249747 | Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis |
Q42384700 | Dual bronchodilation and exacerbations of COPD. |
Q26752988 | Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA |
Q36223222 | Dyspnea, depression and health related quality of life in pulmonary arterial hypertension patients |
Q39677216 | E pluribus plurima: multidimensional indices and clinical phenotypes in COPD |
Q36636050 | Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations |
Q50033239 | Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. |
Q55485805 | Effect of Liuzijue Exercise Combined with Elastic Band Resistance Exercise on Patients with COPD: A Randomized Controlled Trial. |
Q90729065 | Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels and Quality of Life at One Year |
Q24635347 | Effect of doxycycline in patients of moderate to severe chronic obstructive pulmonary disease with stable symptoms |
Q34198955 | Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis |
Q94553029 | Effect of procalcitonin on the prognosis of patients with COPD |
Q64079595 | Effectiveness and Safety of Oral on Stable COPD of GOLD Stages 2-3: Systematic Review and Meta-Analysis |
Q47879585 | Effectiveness of a Respiratory Day Hospital Program to Reduce Admissions for Exacerbation in Patients with Severe COPD: A Prospective, Multicenter Study |
Q34033143 | Effectiveness of the Assessment of Burden of Chronic Obstructive Pulmonary Disease (ABC) tool: study protocol of a cluster randomised trial in primary and secondary care |
Q36704580 | Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD. |
Q64245613 | Effects of Different Comorbidities on Health-Related Quality of Life among Respiratory Patients in Vietnam |
Q35766357 | Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease |
Q37785279 | Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease |
Q37110198 | Efficacy and Safety of Roflumilast in Korean Patients with COPD. |
Q38604641 | Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study |
Q35686996 | Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial |
Q48485039 | Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). |
Q37209291 | Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study |
Q46576729 | Efficacy and safety of bronchoscopic lung volume reduction therapy in patients with severe emphysema: a meta-analysis of randomized controlled trials |
Q21257191 | Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study |
Q54467741 | Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. |
Q34995066 | Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease |
Q44756130 | Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. |
Q38604621 | Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities |
Q34316776 | Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis |
Q37555782 | Efficacy of tiotropium in the prevention of exacerbations of COPD. |
Q28075367 | Efficacy of tiotropium-olodaterol fixed-dose combination in COPD |
Q36526988 | Eight-step method to build the clinical content of an evidence-based care pathway: the case for COPD exacerbation |
Q54963373 | Emerging Evidence of Thresholds for Beneficial Effects from Vitamin D Supplementation. |
Q28383300 | Emphysema predicts hospitalisation and incident airflow obstruction among older smokers: a prospective cohort study |
Q39435739 | Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. |
Q34940755 | Endogenous testosterone level and testosterone supplementation therapy in chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. |
Q51599981 | Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. |
Q34984451 | Evaluation of correlation of BODE index with health-related quality of life among patients with stable COPD attending a tertiary care hospital |
Q33554553 | Evaluation of malnutrition detected with the Nutritional Risk Screening 2002 (NRS-2002) and the quality of life in hospitalized patients with chronic obstructive pulmonary disease |
Q39627403 | Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies |
Q30949429 | Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data. |
Q26745663 | Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease |
Q37862607 | Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. |
Q58579811 | Flow and volume response to bronchodilator in patients with COPD |
Q93184812 | Forced expiratory volumes in 3 s is a sensitive clinical measure for assessment of bronchodilator reversibility in elderly Chinese with severe lung function impairment |
Q37416866 | From large clinical trials to management of COPD in the real world |
Q33509146 | From proteomics to prescription-the search for COPD biomarkers |
Q51559494 | Functional respiratory imaging (FRI) for optimizing therapy development and patient care. |
Q35936008 | Gaps in using bronchodilators, inhaled corticosteroids and influenza vaccine among 23 high- and low-income sites |
Q38081908 | Growing awareness of the importance of health literacy in individuals with COPD. |
Q34445946 | Health effects of the Federal Bureau of Prisons tobacco ban. |
Q92331842 | Health-related quality of life of patients diagnosed with COPD in Extremadura, Spain: results from an observational study |
Q89964040 | Healthcare Professionals' Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease |
Q45803920 | Impact and prevention of severe exacerbations of COPD: a review of the evidence |
Q38655574 | Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. |
Q34511113 | Improving communication between the physician and the COPD patient: an evaluation of the utility of the COPD Assessment Test in primary care |
Q26851664 | Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol |
Q38072277 | Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective |
Q34962838 | Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis |
Q48059168 | Indacaterol for the treatment of chronic obstructive pulmonary disease |
Q34243574 | Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. |
Q37778736 | Indacaterol: a new once daily long-acting beta2 adrenoceptor agonist |
Q37987211 | Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease |
Q57117321 | Influence of air pressure, humidity, solar radiation, temperature, and wind speed on ambulatory visits due to chronic obstructive pulmonary disease in Bavaria, Germany |
Q38153757 | Inhaled corticosteroids for chronic obstructive pulmonary disease |
Q34888769 | Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis |
Q47661714 | Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. |
Q37199668 | Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies |
Q47907472 | Integrated multidisciplinary community service for chronic obstructive pulmonary disease reduces hospitalisations |
Q37622935 | Is there a role for antiinflammatory treatment in COPD? |
Q30581769 | Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts |
Q24194044 | Long-acting beta 2 -agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease |
Q24197853 | Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis |
Q38388302 | Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease |
Q38646619 | Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis |
Q39548676 | Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease. |
Q61800223 | Longitudinal change of FEV 1 and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD |
Q46075418 | Longitudinal changes in patient-reported dyspnea in patients with COPD. |
Q45392088 | Longitudinal lung volume changes in patients with chronic obstructive pulmonary disease |
Q94355405 | Long‐acting beta‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease |
Q64319638 | Low income as a determinant of exercise capacity in COPD |
Q35994827 | Lung development and the host response to influenza A virus are altered by different doses of neonatal oxygen in mice |
Q34206825 | Lung function decline in relation to diagnostic criteria for airflow obstruction in respiratory symptomatic subjects |
Q37168317 | Markers of early disease and prognosis in COPD. |
Q35672964 | Measurement of C-reactive protein, procalcitonin and neutrophil elastase in saliva of COPD patients and healthy controls: correlation to self-reported wellbeing parameters |
Q38175163 | Minimal clinically important differences in pharmacological trials |
Q37421246 | Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study |
Q51717909 | Minimum clinically important difference in diffusing capacity of the lungs for carbon monoxide among patients with severe and very severe chronic obstructive pulmonary disease. |
Q31130295 | Multifractal analysis for nutritional assessment |
Q87646805 | N-acetylcysteine for COPD: the evidence remains inconclusive--authors' reply |
Q26768289 | N-acetylcysteine in COPD: why, how, and when? |
Q37220006 | N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD |
Q41838638 | Natural histories of chronic obstructive pulmonary disease |
Q38059466 | Nebulized arformoterol: what is its place in the management of COPD? |
Q34768711 | Neuromuscular electrical stimulation improves exercise tolerance in chronic obstructive pulmonary disease patients with better preserved fat-free mass |
Q37390883 | New developments in the management of COPD: clinical utility of indacaterol 75 μg. |
Q37589154 | New drugs for exacerbations of chronic obstructive pulmonary disease |
Q38083537 | No room to breathe: the importance of lung hyperinflation in COPD. |
Q94571769 | Objective secondhand smoke exposure in chronic obstructive pulmonary disease patients without active smoking: the U.S. National Health and Nutrition Examination Survey (NHANES) 2007-2012 |
Q92156772 | Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease |
Q94347856 | Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease |
Q41844550 | Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial |
Q47192702 | Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life. |
Q36196805 | Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial |
Q42170464 | Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium |
Q27010444 | Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy |
Q34154974 | Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect |
Q38477843 | Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study |
Q45560084 | Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. |
Q30480535 | Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations |
Q38633304 | Oxidation pathway and exacerbations in COPD: the role of NAC. |
Q36485759 | Patient's perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL Study |
Q45757076 | Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe |
Q34519035 | Patient-reported dyspnea in COPD reliability and association with stage of disease |
Q36275067 | Patterns and characterization of COPD exacerbations using real-time data collection |
Q33706037 | Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities |
Q92703042 | Pharmacogenomics of chronic obstructive pulmonary disease |
Q89122759 | Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis |
Q38817813 | Pharmacological management of breathlessness in COPD: recent advances and hopes for the future |
Q28070274 | Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review |
Q37924598 | Pharmacological treatment of COPD. |
Q36254441 | Pharmacological treatment response according to the severity of symptoms in patients with chronic obstructive pulmonary disease |
Q64097299 | Plasma cathelicidin and longitudinal lung function in current and former smokers |
Q43297227 | Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. |
Q35111729 | Predictors of ICS/LABA prescribing in COPD patients: a study from general practice |
Q37392322 | Prevalence of alpha-1 antitrypsin deficiency and allele frequency in patients with COPD in Brazil |
Q37896372 | Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease |
Q40786706 | Prognostic assessment in COPD without lung function: the B-AE-D indices. |
Q36048443 | Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD. |
Q34948185 | Proteomic differences with and without ozone-exposure in a smoking-induced emphysema lung model |
Q38154291 | Pulmonary biomarkers in COPD exacerbations: a systematic review |
Q92119093 | Pulmonary function decreases moderately after accelerated high-dose irradiation for stage III non-small cell lung cancer |
Q34798279 | Putting health status guided COPD management to the test: protocol of the MARCH study. |
Q38194114 | QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease |
Q46271491 | Quality indicators for in-hospital management of exacerbation of chronic obstructive pulmonary disease: results of an international Delphi study |
Q36759415 | Quantitative analysis of hyperpolarized 129Xe ventilation imaging in healthy volunteers and subjects with chronic obstructive pulmonary disease |
Q34632774 | RECODE: design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care |
Q35011666 | Radiological correlates and clinical implications of the paradoxical lung function response to β₂ agonists: an observational study |
Q39758240 | Regional lung response to bronchodilator reversibility testing determined by electrical impedance tomography in chronic obstructive pulmonary disease. |
Q35751737 | Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease |
Q28484224 | Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum |
Q36284259 | Reproducibility of optical coherence tomography airway imaging |
Q33715834 | Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease. |
Q38137141 | Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. |
Q33824534 | Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials |
Q37681577 | Roflumilast in chronic obstructive pulmonary disease: evidence from large trials |
Q38730318 | Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease |
Q37303247 | Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. |
Q35822151 | Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients |
Q91566045 | Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine |
Q41400534 | Saving Time for Patients with Moderate to Severe COPD: Endurance Test Speed Set Using Usual and Fast Walk Speeds. |
Q37589149 | Screening for and early detection of chronic obstructive pulmonary disease |
Q35042489 | Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease |
Q38604595 | Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials |
Q37168340 | Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations |
Q58840506 | Systemic Effects of COPD: Just the Tip of the Iceberg |
Q37765755 | Systemic corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease |
Q38056532 | Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease |
Q58718347 | Telehealth for patients with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis protocol |
Q55154201 | Telerehabilitation versus traditional centre-based pulmonary rehabilitation for people with chronic respiratory disease: protocol for a randomised controlled trial. |
Q47962475 | The Challenges of Precision Medicine in COPD. |
Q37389639 | The Effect of Fatigue and Fatigue Intensity on Exercise Tolerance in Moderate COPD. |
Q37248009 | The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension |
Q26828971 | The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease |
Q33817770 | The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients |
Q37698333 | The clinical chronic obstructive pulmonary disease questionnaire: cut point for GOLD 2013 classification. |
Q36982645 | The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease |
Q38832398 | The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease |
Q36308010 | The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency. |
Q36300138 | The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases |
Q37930205 | The future of chronic obstructive pulmonary disease treatment--difficulties of and barriers to drug development |
Q41908094 | The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients |
Q64101434 | The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects |
Q38052955 | The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease |
Q91878017 | The prognostic values of neutrophil to lymphocyte ratio for outcomes in chronic obstructive pulmonary disease |
Q36438669 | The role of bronchodilator treatment in the prevention of exacerbations of COPD. |
Q38095144 | The role of desmosines as biomarkers for chronic obstructive pulmonary disease |
Q38077797 | The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease |
Q22305858 | The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary disease |
Q34779478 | Three-month treatment response and exacerbation in chronic obstructive pulmonary disease. |
Q26780553 | Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma |
Q24194833 | Tiotropium versus placebo for chronic obstructive pulmonary disease |
Q24202175 | Tiotropium versus placebo for chronic obstructive pulmonary disease |
Q37419691 | Trachea epithelium as a "canary" for cigarette smoking-induced biologic phenotype of the small airway epithelium |
Q39642495 | Transition of patients with COPD across different care settings: challenges and opportunities for hospitalists |
Q38060087 | Treating the small airways |
Q48710242 | Treatment of advanced emphysema with emphysematous lung sealant (AeriSeal®). |
Q42260506 | Triple Therapy for Moderate-to-Severe Chronic Obstructive Pulmonary Disease. |
Q37868010 | Triple therapy for the management of COPD: a review |
Q42920605 | Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide |
Q54264691 | Tuberculosis and lung damage: from epidemiology to pathophysiology. |
Q38248438 | Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD. |
Q37422824 | Update in chronic obstructive pulmonary disease 2008. |
Q38241442 | Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease |
Q87695799 | Updates in Chronic Obstructive Pulmonary Disease for the Year 2014 |
Q37944316 | Utility estimation in chronic obstructive pulmonary disease: a preference for change? |
Q35710238 | V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results |
Q33824230 | Validation and development of an immunonephelometric assay for the determination of alpha-1 antitrypsin levels in dried blood spots from patients with COPD. |
Q91950215 | Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease |
Q51066326 | Validity of a Self-administered Questionnaire Version of the Transition Dyspnea Index in Patients with COPD. |
Q39219255 | Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial |
Q36718728 | Warm homes for older people: aims and methods of a randomised community-based trial for people with COPD |
Q35945635 | Which field walking test should be used to assess functional exercise capacity in lung cancer? An observational study |
Q49047172 | Why doesn't reducing exacerbations decrease COPD mortality? |
Q83445498 | [Patient-reported parameters in chronic obstructive pulmonary disease] |
Q82954791 | [Pelargonium sidoides in acute bronchitis - Health-related quality of life and patient-reported outcome in adults receiving EPs 7630 treatment] |
Q79690690 | [Should we screen for COPD in the population] |
Search more.